These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 3025013)

  • 1. Poliomyelitis immunity status at different intervals from vaccination.
    Bellelli E; Bracchi U; Tanzi ML; Benaglia G; Montanarini G
    Eur J Epidemiol; 1986 Sep; 2(3):197-204. PubMed ID: 3025013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass vaccination campaigns to eradicate poliomyelitis in Madagascar: oral poliovirus vaccine increased immunity of children who missed routine programme.
    Andrianarivelo MR; Boisier P; Rabarijaona L; Ratsitorahina M; Migliani R; Zeller H
    Trop Med Int Health; 2001 Dec; 6(12):1032-9. PubMed ID: 11737841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine.
    Moriniere BJ; van Loon FP; Rhodes PH; Klein-Zabban ML; Frank-Senat B; Herrington JE; Pallansch MA; Patriarca PA
    Lancet; 1993 Jun; 341(8860):1545-50. PubMed ID: 8099637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipoliomyelitis immunity status among a population that was regularly vaccinated 11-12 years before.
    Bellelli E; Tanzi ML; Bocelli V; Bracchi U; Affanni P
    Eur J Epidemiol; 1991 Nov; 7(6):605-11. PubMed ID: 1664344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial.
    Estívariz CF; Jafari H; Sutter RW; John TJ; Jain V; Agarwal A; Verma H; Pallansch MA; Singh AP; Guirguis S; Awale J; Burton A; Bahl S; Chatterjee A; Aylward RB
    Lancet Infect Dis; 2012 Feb; 12(2):128-35. PubMed ID: 22071249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-lasting poliovirus-neutralizing antibodies among Argentinean population immunized with four or five oral polio vaccine doses 1 month to 19 years previously.
    Nates SV; Martinez LC; Barril PA; Ferreyra LJ; Giordano MO; Masachessi G; Isa MB
    Viral Immunol; 2007; 20(1):3-10. PubMed ID: 17425416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programmes.
    Richardson G; Linkins RW; Eames MA; Wood DJ; Campbell PJ; Ankers E; Deniel M; Kabbaj A; Magrath DI; Minor PD
    Bull World Health Organ; 1995; 73(6):769-77. PubMed ID: 8907770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential use of inactivated poliovirus vaccine followed by oral poliovirus vaccine in Oman.
    Sutter RW; Suleiman AJ; Malankar PG; Mehta FR; Medany MA; Arif MA; Linkins RW; Pallansch MA; El-Bualy MS; Robertson SE
    J Infect Dis; 1997 Feb; 175 Suppl 1():S235-40. PubMed ID: 9203722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poliomyelitis vaccination of infants: preimmunization status and seroconversion.
    Choudhury DS; Nossik NN; Bindu ; Vijayan P; Raghavan NG; Paul SS
    Bull World Health Organ; 1973; 48(2):195-8. PubMed ID: 4352611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiological analysis of immunity to poliovirus after termination of an era of vaccination with OPV in Germany. An analysis of the German Association Against Viral Diseases (DVV).
    Franck S; Allwinn R; Rabenau HF; Doerr HW
    Zentralbl Bakteriol; 1999 Oct; 289(4):475-81. PubMed ID: 10603664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [VACCINE-ASSOCIATED PARALYTIC POLIOMYELITIS IN RUSSIAN FEDERATION DURING THE PERIOD OF CHANGES IN VACCINATION SCHEDULE (2006-2013 yy.)].
    Ivanova OE; Eremeeva TP; Morozova NS; Shakaryan AK; Gmyl AP; Yakovenko ML; Korotkova EA; Chernjavskaja OP; Baykova OY; Silenova OV; Krasota AY; Krasnoproshina LI; Mustafina AN; Kozlovskaja LI
    Vopr Virusol; 2016; 61(1):9-15. PubMed ID: 27145594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroprevalence of antibody against poliovirus in inner-city preschool children. Implications for vaccination policy in the United States.
    Chen RT; Hausinger S; Dajani AS; Hanfling M; Baughman AL; Pallansch MA; Patriarca PA
    JAMA; 1996 Jun; 275(21):1639-45. PubMed ID: 8637136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age differences in immunity against wild and vaccine strains of poliovirus prior to the 1988 outbreak in Israel and response to booster immunization.
    Green MS; Handsher R; Cohen D; Melnick JL; Slepon R; Mendelsohn E; Danon YL
    Vaccine; 1993; 11(1):75-81. PubMed ID: 8381249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global eradication of poliomyelitis: reinvent the wheel or use existing options effectively?
    Ogra PL
    Public Health Rev; 1993-1994; 21(1-2):143-50. PubMed ID: 8041881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
    O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
    Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines.
    Faden H; Duffy L; Sun M; Shuff C
    J Infect Dis; 1993 Aug; 168(2):452-4. PubMed ID: 8335983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody response of children immunized with poliovaccines: an evaluation using two strains of poliovirus type 1.
    Deshpande JM; Dave KH
    Indian J Med Res; 1992 Sep; 95():216-20. PubMed ID: 1335965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunity against poliomyelitis in the Netherlands, assessed in 2006 to 2007: the importance of completing a vaccination series.
    van der Maas NA; Mollema L; Berbers GA; van Rooijen DM; van der Avoort HG; Conyn-Van Spaendonck MA; de Melker HE; van der Klis FR
    Euro Surveill; 2014 Feb; 19(7):20705. PubMed ID: 24576472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent oral poliovirus and rhesus-human reassortant rotavirus vaccination: effects on immune responses to both vaccines and on efficacy of rotavirus vaccines. The US Rotavirus Vaccine Efficacy Group.
    Rennels MB; Ward RL; Mack ME; Zito ET
    J Infect Dis; 1996 Feb; 173(2):306-13. PubMed ID: 8568290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A comparison of the effectiveness of mass immunization campaign of trivalent oral poliovirus vaccine (TOPV) by epidemiological serosurvey. Shandong Collaborating Group for Poliomyelitis Control and Surveillance, Jinan, Shandong].
    Xu A
    Zhonghua Liu Xing Bing Xue Za Zhi; 1992 Oct; 13(5):261-4. PubMed ID: 1338626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.